39 / 56
39
Educational Seminars
Friday, 21 April 2017
ME-02
Meet-the-Expert-Session
17:45–18:45
Ballroom A
Guidelines for assessing adverse events associated
to ADHD medication
Chair: A. Zuddas, Italy
Description
Medications for ADHD are generally well-tolerated.
In the short term, both common and usually mild, as
well as rare but severe adverse events may be observed
during drug treatment: They are usually manageable and
most of the times it is not necessary to stop medication,
so that patients with ADHD may continue to benefit
from the effectiveness of pharmacological treatment.
It should be considered, however, that whilst the short
term efficacy, safety and tolerability of medication as a
treatment for ADHD in children and adolescents is very
well-established, the longer term benefits and risks are
much less well defined.
Following the European Medicine Agency (EMA)
requirements for registration of new medicines, the FP7
funded Attention Deficit Hyperactivity Disorder Drugs
Use Chronic Effects (ADDUCE) study was designed
to address the longer term safety and tolerability of
methylphenidate by combinig existing informations
(literatire systematic reivew and data mining form
available data-bases) and the results of a large multisite,
pan-European prospective two years safety trial.
In order to provide updated guidelines for assessing
adverse events associated with ADHD medication, the
main findings af the ADDUCE studies will be presented
and discussed, also comparing available information
on other medications, covering their long-term safety
across different safety domains such as the growth,
cardiovascular and psychiatric adverse effects.
ME-03
Meet-the-Expert-Session
17:45–18:45
Ballroom BC
New advances on ADHD genetics and how they
might inform clinical practice
Chair: M. Bellgrove, USA
Description
Genetics research of ADHD has reached a watershed
moment with recent expansion of the collections
of the Psychiatric Genetics Consortium (PGC) now
identifying replicable genome-wide associations for
ADHD. In addition, the advent of DNA sequencing
technologies such as whole exome and whole genome
sequencing looms large on the horizon. With all
these discoveries there is much for the clinician to
digest. This presentation will provide a state-of-the-art
overview of our current understanding of the genetics
of ADHD. It will review findings from candidate gene
and genome-wide association methodologies and
highlight the emerging space of DNA sequencing.
It will discuss recent work revealing relationships
between cumulative (polygenic) genetic risk and
clinical outcomes (e.g., symptom persistence) and
the potential role of pharmacogenetics for driving a
personalised medicine approach to clinical practice.